#10 million people fell ill with TB

[mediaheights]

World Tuberculosis Day, observed on 24 March each year, is designed to build public awareness about the global epidemic of tuberculosis and efforts to eliminate the disease. In 2018, 10 million people fell ill with TB, and 1.5 million died from the disease, mostly in low and middle-income countries. Build your brand with digital media & take the benefits of social media branding contact Media Heights. By Mediaheightspr.com #worldtbdday #Inboundmarketing #MEDIAHEIGHTS #digitalmarketingcompany #searchengineoptimization #content #instagrammarketing #advertisingagency #web #MEDIAHEIGHTSPRCOM #best #public #relation #agency #in #chandigarh #mohali #punjab #north #india #buildingrelationships #globally #customer #internetbanding — at media heights #smo #branding #facebook #twitter #marketingonline #brand #searchengineoptimization #internetmarketing #follow #digitalagency #marketingagency #motivation #digitalmarketingtips #onlinebusiness #websitedesign #marketingonline #brand #searchengineoptimization #content #instagrammarketing #advertisingagency #web #technology #onlinebranding #branding360degree #SEO #SEObrandingagency #websiteranking #websitetrafic #Digitalmarketing #mediaheights #OnlineAdvertising #instagrammarketing #advertisingagency #web #marketingonline #brand

[decentralvaccine]

Time To Revamp The TB Vaccine

This ancient disease, known today as tuberculosis or TB, has plagued humanity for thousands of years, and as recently as a few hundred years ago, was thought to be responsible for some 25 percent of all deaths in Europe and North America.

Today, TB is both preventable and treatable — there’s a century-old vaccine, effective antibiotics, and known behavioral and sanitation safeguards that disrupt transmission. Yet in 2022, more than 10 million people globally still fell ill from TB and 1.3 million died, making it the second deadliest infectious disease that year. (More people die from TB generally, but Covid-19 temporarily outpaced it.) More than 80 percent of those TB cases and deaths occur in low- and middle-income countries.

https://www.vox.com/future-perfect/24128530/tuberculosis-vaccine-efficacy-solutions-tb-bcg

[livesanskrit]

Send from Sansgreet Android App. Sanskrit greetings app from team @livesanskrit .

It's the first Android app for sending @sanskrit greetings. Download app from https://livesanskrit.com/sansgreet

World Tuberculosis Day.

World Tuberculosis Day, observed on 24 March each year, is designed to build public awareness about the global epidemic of tuberculosis (TB) and efforts to eliminate the disease. In 2018, 10 million people fell ill with TB, and 1.5 million died from the disease, mostly in low and middle-income countries. This also makes it the leading cause of death from an infectious disease.

#sansgreet #sanskritgreetings #greetingsinsanskrit #sanskritquotes #sanskritthoughts #emergingsanskrit #sanskrittrends #trendsinsanskrit #livesanskrit #sanskritlanguage #sanskritlove #sanskritdailyquotes #sanskritdailythoughts #sanskrit #resanskrit #worldtuberculosisday #tuberculosisday #tuberculosis #publicawareness #awareness #tb #celebratingsanskrit #who #robertkoch #worldtbday #tbday #worldhealthorganization #hiroshi #endtb #disease

[techninja]

Bridging the Gap: Access and Distribution in the Human Tuberculosis Vaccine Market

Introduction

Tuberculosis (TB) remains a global health challenge, with millions of people affected each year. The development of an effective human tuberculosis vaccine has been a priority in the fight against this infectious disease. In recent years, significant advancements have been made in this field, offering hope for the control and eventual eradication of TB. This article explores the current state of the Human Tuberculosis Vaccine Market, including the challenges and opportunities it presents.

The Global Burden of Tuberculosis

Tuberculosis is a bacterial infection caused by Mycobacterium tuberculosis. It primarily affects the lungs but can also impact other parts of the body. Despite substantial progress in controlling the disease, TB remains a major public health threat, especially in developing countries. In 2019, approximately 10 million people fell ill with TB, and 1.4 million lost their lives due to the disease, according to the World Health Organization.

The Need for a TB Vaccine

The TB vaccine, known as the Bacille Calmette-Guérin (BCG) vaccine, has been in use for nearly a century. While it offers some protection against severe forms of TB in children, it has limited effectiveness against the more common and contagious forms of the disease in adults. The need for a more effective TB vaccine is clear, as drug-resistant strains of the bacterium are on the rise, making it even more challenging to control the spread of the disease.

Advancements in TB Vaccine Research

In recent years, there has been significant progress in TB vaccine research. Several vaccine candidates are in various stages of development and clinical trials. One notable candidate is the M72/AS01E vaccine, which showed promise in Phase 2 trials. This vaccine is intended for adults and aims to provide protection against TB infection.

Another promising candidate is VPM1002, which is a modified version of the existing BCG vaccine. It is being tested in clinical trials to evaluate its safety and efficacy. Additionally, other vaccines like H4:IC31 and ID93 + GLA-SE are under investigation, indicating a diverse range of approaches being explored in the quest for a TB vaccine.

Challenges in TB Vaccine Development

Developing a successful TB vaccine presents unique challenges. The bacterium's complex biology, the need for long-term protection, and the high variability of TB strains make vaccine development a difficult endeavor. Furthermore, the cost and time required for vaccine development and clinical testing are substantial hurdles.

Access and Distribution

Even with successful vaccine development, ensuring equitable access and distribution remains a significant challenge. TB predominantly affects low- and middle-income countries, where access to healthcare services and vaccines can be limited. Overcoming these barriers to vaccine distribution and affordability is crucial to effectively combat TB on a global scale.

Conclusion

The Human Tuberculosis Vaccine Market is at a critical juncture. Advancements in research and development offer hope for a more effective TB vaccine, which is desperately needed to combat this global health crisis. However, challenges in vaccine development, distribution, and accessibility must be addressed for meaningful progress to be made. The collaborative efforts of governments, pharmaceutical companies, and global health organizations are essential in the fight against tuberculosis. With continued dedication and innovation, a more effective TB vaccine may become a reality, reducing the global burden of this deadly disease and saving countless lives.

Few Other Promising Reports in Pharmaceutical Industry

Global Major Depressive Disorder (MDD) Treatment Market

Neuromodulation Devices Market

Mental Disorder Treatment Market

Serotonin Norepinephrine Inhibitor Market

[abcd-meds]

Read more: Tuberculosis

World Tuberculosis (TB) Day is observed on March 24th every year to raise public awareness about the devastating health, social, and economic consequences of TB. The day also aims to step up efforts to end the global TB epidemic.

The day marks the anniversary of the discovery of the TB bacteria by Dr. Robert Koch in 1882. Since then, TB has been a major public health issue, affecting people all over the world. According to the World Health Organization (WHO), TB is one of the top 10 causes of death worldwide, and in 2020, an estimated 10 million people fell ill with TB, with 1.4 million dying from the disease.

World TB Day provides an opportunity to raise awareness about the burden of TB and the efforts to eliminate the disease. The theme for World TB Day 2023 is "Find. Treat. All. #EndTB", which highlights the importance of finding and treating all people with TB, including those who may be overlooked or marginalized.

The WHO, in collaboration with partners and governments, has set ambitious targets to end the TB epidemic by 2030, which include reducing TB deaths by 90% and TB incidence by 80% compared to 2015 levels. Achieving these targets will require a concerted effort to improve access to TB prevention, diagnosis, treatment, and care, as well as addressing the social determinants that contribute to the spread of the disease.

On World TB Day, events and activities are organized all over the world to raise awareness about TB, share information about the disease, and mobilize support for TB control efforts. These activities may include health talks, screenings, community outreach programs, marches, and advocacy campaigns.

Overall, World TB Day is an important reminder that TB remains a major global health threat, but it also offers hope that with continued efforts, we can end the TB epidemic and ensure a healthier future for all.

[bpod-bpod]

Quicker Fix

Until SARS-CoV-2, the bacteria Mycobacterium tuberculosis (pictured) held the top spot as the world’s most deadly infectious agent. Approximately 10 million people fell ill as a result of the bacteria in 2019, and approximately 1.4 million of them died. Tuberculosis, which mostly affects the lungs causing a thick phlegmy cough, fever and weight loss, can be cured, but the hefty drug regimen involves a cocktail of several different antibiotics taken for six months or more. A recent trial involving more than 2000 TB patients, however, has shown that a four-month course of antibiotics can be equally as effective at eliminating the disease. And that’s good news because a shorter course means not only cheaper treatment – especially important for the less affluent countries where TB is prevalent – but also, that any side effects of the drugs, such as stomach upsets, loss of appetite, and itchy skin are also resolved faster.

Written by Ruth Williams

Image by the National Institute of Allergy and Infectious Diseases (NIAID)

Research by Susan E. Dorman, Payam Nahid and Ekaterina V. Kurbatova, and colleagues, UCSF Center for Tuberculosis, University of California, San Francisco, CA, USA and other institutes

Image copyright held by the NIAID

Research published in New England Journal of Medicine, May 2021

You can also follow BPoD on Instagram, Twitter and Facebook

[biotechgreenyindia]

#World  Tuberculosis Day, observed on 24 March each year, is designed to build public awareness about the global epidemic of tuberculosis and efforts to eliminate the disease. In 2018, 10 million people fell ill with TB, and 1.5 million died from the disease, mostly in low and middle-income countries.

Call us - +91 6386107092

#greenyindia #indoorplants #bedroomplants #officedeskplants #fruitplantsinpot #landscapingcompany #verticalgardening #terracegardening #plantsshop #hangingplants #buyflowersonline #flowersonline #flowersonlineshop #flowersonlinegarden #flowersonlinedelivery #flowersonlinedeliveryindia

[idoc-x]

Tuberculosis control — Artificial Intelligence is now becoming integral!

Artificial intelligence (AI) is key nowadays to harnessing data and insight to deliver better healthcare. AI platforms can ingest a vast amount of information of varying types (text /audio/ video/ images numbers and others). This enables doctors, clinicians, physicians and researchers to find correlations and insights not possible before eventually leading to better, faster and sometimes new discoveries and treatments. In summary, AI systems compliment human knowledge, as the volume and pace of healthcare data continue to explode.

Tuberculosis (TB) has been around now for decades. It is a contagious bacterial infection which spreads through the air via cough, sneeze etc and usually infects lungs but can also impact other organs of the body. As per WHO, an estimated 10 million people fell ill with tuberculosis (TB) worldwide in 2019(5.6 million men, 3.2 million women and 1.2 million children). A total of 1.4 million people died from TB in 2019 (including 208000 people with HIV). Worldwide, TB is one of the top 10 causes of death and the leading cause of a single infectious agent (above HIV/AIDS).

The WHO’s End TB strategy goal between 2016 and 2035 is to reduce worldwide TB incidence by 90% and TB mortality by 95%. The areas to focus for countries targeting to reduce their TB burden (by 2035) are digital health care, surveillance, better programme management, professional training and efficient communication. The focus is also on improved access to medical care, especially diagnostic tests.

Artificial Intelligence is making deep inroads into TB diagnosis and treatment via deep learning insights into radiology and pathology, thus helping enormously in the early and accurate detection of TB so that required treatment can be provided.

In radiology, the emphasis is on automated detection of TB on digital chest radiographs. TB is a challenging diagnosis to make due to varied radiographic presentation and it is very similar to another disease like pneumonia, edema etc. In the past few decades, automated screening and detection of TB have moved gradually from CAD (computer-aided detection) programs to CNN (convolutional neural network) and deep learning AI programs because of their higher accuracy and speed of analysing radiological images. These AI programs have been able to augment and compliment radiologists across the globe.

At iDoc.ai (https://idoc.ai/) , Swindon, UK — we are working towards pragmatic & practical AI solutions to specifically address the issues around Radiology. AI can augment Radiologist and can provide much-needed support under current circumstances.

Pathology is another important avenue for diagnosing TB. It is critical to find specially stained TB bacilli to detect and confirm TB diagnosis. This is a very difficult task to do and repeat due to very small size and the number of bacilli TB bacilli. Even for experienced pathologists this is quite strenuous and leads to delays, low detection rate and false diagnoses. AI results have been promising to detect stained TB bacilli and help clinicians to make accurate decisions. It reduces the workload of pathologists and minimizes chances of missed diagnosis.

The persistent gap in the detection of TB is the primary reason for the high mortality. AI has evolved at a rapid pace to bridge that gap and help radiologists and pathologists make better, accurate, well informed and timely decisions.

[kellymarchent242]

24 March Special Day: Know About World Tuberculosis Day

World Tuberculosis Day

World Tuberculosis Day, observed on 24 March each time, is designed to make the public mindful of the global epidemic of tuberculosis (TB) and sweats to exclude the complaint. In 2018, 10 million people fell ill with TB, and1.5 a million failed from the complaint, substantially in low and middle-income countries. This also makes it the leading cause of death from a contagious complaint.

World TB Day is one of eleven sanctioned global public health juggernauts marked by the World Health Organization (WHO), along with World Health Day, World Chagas Disease Day, World Blood Donor Day, World Antimicrobial Awareness Week, World Immunization Week, World Malaria Day, World No Tobacco Day, World Hepatitis Day, World Patient Safety Day and World AIDS Day.

[social-mania]

TB remains world’s deadliest infectious disease: WHO

Health News : Tuberculosis (TB) remains the world’s deadliest infectious disease although global efforts have averted an estimated 54 million tuberculosis (TB) deaths since 2000, the World Health Organization (WHO) warned on Tuesday.

WHO, in its latest 2018 Global TB Report, says countries are still not doing enough to end TB by 2030 and calls for an unprecedented mobilization of national and international commitments. It urges for decisive action from nearly 50 heads of state and government who are expected to gather next week for the first-ever UN High-level Meeting on TB, Xinhua news agency reported.

The report finds that overall, TB deaths have decreased over the past year, with an estimated 10 million people having developed TB and 1.6 million deaths, including among 300,000 HIV-positive people, in 2017. The number of new cases is falling by two percent per year.

However, underreporting and under-diagnosis of TB cases remains a major challenge. Of the 10 million people who fell ill with TB in 2017, only 6.4 million were officially recorded by national reporting systems…Read more

[jnsupermom]

World Tuberculosis Day! Let's spread awareness! Did you know that it was March 24 in 1882 when Dr. Robert Koch shared his discovery of Mycobacterium tuberculosis, which at this time was killing 1 out of every 7 living in the USA and Europe. This bacteria causes Tuberculosis and is preventable and curable. Spread through the air from person to person, usually affecting the lungs, however it can also affect the brain, kidneys or spine. TB is a global epidemic devastating many to this day. According to the WHO "World Health Organization" • A total of 1.5 million people died from TB in 2020 (including 214 000 people with HIV). Worldwide, TB is the 13th leading cause of death and the second leading infectious killer after COVID-19 (above HIV/AIDS). • In 2020, an estimated 10 million people fell ill with tuberculosis (TB) worldwide. 5.6 million men, 3.3 million women and 1.1 million children. TB is present in all countries and age groups. But TB is curable and preventable. • In 2020, 1.1 million children fell ill with TB globally. Child and adolescent TB is often overlooked by health providers and can be difficult to diagnose and treat. To read more aboutTuberculosis and the statistics surrounding its impact please visit. https://www.who.int/news-room/fact-sheets/detail/tuberculosis #WorldTuberculosisDay2022 #tuberculosisawareness #tuberculosis #tuberculosisday https://www.instagram.com/p/Cbfis98LGxZ/?utm_medium=tumblr

[easylearningindia]

World TB Day 24 March World Tuberculosis Day, observed on 24 March each year, is designed to build public awareness about the global epidemic of tuberculosis and efforts to eliminate the disease. In 2018, 10 million people fell ill with TB, and 1.5 million died from the disease, mostly in low and middle-income countries. . . . #easylearningindia #worldtbday #tb #tuberculosis #worldtuberculosisday #worldtuberculosisday2022 #tb #24march #likeforlikes #shareforshare https://www.instagram.com/p/Cbe4wFqP1rf/?utm_medium=tumblr

[eventsthings]

World Tuberculosis Day, observed on 24 March each year, is designed to build public awareness about the global epidemic of tuberculosis and efforts to eliminate the disease. In 2018, 10 million people fell ill with TB, and 1.5 million died from the disease, mostly in low and middle-income countries. #people #india #awareness #sgduniversalprivatelimited #entertainmentindustry #foodindustry #fashionindustry #eventindustry #television #entertainment #worldtuberculosisday #disease

[rootbuildconpvtltd]

World Tuberculosis Day, observed on 24 March each year, is designed to build public awareness about the global epidemic of tuberculosis and efforts to eliminate the disease. In 2018, 10 million people fell ill with TB, and 1.5 million died from the disease, mostly in low and middle-income countries #people #worldtuberculosisday #awareness #india #rootbuildconprivatelimited #highwayconstruction #highwayheavyequipment #bitumen #services #constructionindustry #building

[podcastdx]

Tuberculosis/ TB

  On this week's episode we are discussing Tuberculosis, or TB.  Currently the infection has a rate of infection that is only 2.2 per 100,000 persons.  TB is more common in countries where many people live in absolute poverty because people are more likely to:

live and work in poorly ventilated and overcrowded conditions, which provide ideal conditions for TB bacteria to spread

suffer from malnutrition and disease – particularly HIV – which reduces resistance to TB

have limited access to healthcare – and just one person with untreated infectious TB can pass the illness on to 10-15 people annually.

Other TB Facts:

A total of 1.5 million people died from TB in 2020 (including 214 000 people with HIV). Worldwide, TB is the 13th leading cause of death and the second leading infectious killer after COVID-19 (above HIV/AIDS).

In 2020, an estimated 10 million people fell ill with tuberculosis (TB) worldwide. 5.6 million men, 3.3 million women and 1.1 million children. TB is present in all countries and age groups. But TB is curable and preventable.

In 2020, 1.1 million children fell ill with TB globally. Child and adolescent TB is often overlooked by health providers and can be difficult to diagnose and treat.

In 2020, the 30 high TB burden countries accounted for 86% of new TB cases. Eight countries account for two thirds of the total, with India leading the count, followed by China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh and South Africa.

Multidrug-resistant TB (MDR-TB) remains a public health crisis and a health security threat. Only about one in three people with drug resistant TB accessed treatment in 2020.

Globally, TB incidence is falling at about 2% per year and between 2015 and 2020 the cumulative reduction was 11%. This was over half way to the End TB Strategy milestone of 20% reduction between 2015 and 2020.

An estimated 66 million lives were saved through TB diagnosis and treatment between 2000 and 2020.

Globally, close to one in two TB-affected households face costs higher than 20% of their household income, according to latest national TB patient cost survey data. The world did not reach the milestone of 0% TB patients and their households facing catastrophic costs as a result of TB disease by 2020.

By 2022, US$ 13 billion is needed annually for TB prevention, diagnosis, treatment and care to achieve the global target agreed at the UN high level-meeting on TB in 2018.

Funding in low- and middle-income countries (LMICs) that account for 98% of reported TB cases falls far short of what is needed. Spending in 2020 amounted to US$ 5.3 billion less than half (41%) of the global target.

There was an 8.7% decline in spending between 2019 and 2020 (from US$ 5.8 billion to US$ 5.3 billion), with TB funding in 2020 back to the level of 2016.

Ending the TB epidemic by 2030 is among the health targets of the United Nations Sustainable Development Goals (SDGs).

Tuberculosis (TB) is caused by bacteria (Mycobacterium tuberculosis) that most often affect the lungs. Tuberculosis is curable and preventable.

TB is spread from person to person through the air. When people with lung TB cough, sneeze or spit, they propel the TB germs into the air. A person needs to inhale only a few of these germs to become infected.

About one-quarter of the world's population has a TB infection, which means people have been infected by TB bacteria but are not (yet) ill with the disease and cannot transmit it.

People infected with TB bacteria have a 5–10% lifetime risk of falling ill with TB. Those with compromised immune systems, such as people living with HIV, malnutrition or diabetes, or people who use tobacco, have a higher risk of falling ill.

When a person develops active TB disease, the symptoms (such as cough, fever, night sweats, or weight loss) may be mild for many months. This can lead to delays in seeking care, and results in transmission of the bacteria to others. People with active TB can infect 5–15 other people through close contact over the course of a year. Without proper treatment, 45% of HIV-negative people with TB on average and nearly all HIV-positive people with TB will die.

Who is most at risk?

Tuberculosis mostly affects adults in their most productive years. However, all age groups are at risk. Over 95% of cases and deaths are in developing countries.

People who are infected with HIV are 18 times more likely to develop active TB (see TB and HIV section below). The risk of active TB is also greater in persons suffering from other conditions that impair the immune system. People with undernutrition are 3 times more at risk. Globally in 2020, there were 1.9 million new TB cases that were attributable to undernutrition.

Alcohol use disorder and tobacco smoking increase the risk of TB disease by a factor of 3.3 and 1.6, respectively. In 2020, 0.74 million new TB cases worldwide were attributable to alcohol use disorder and 0.73 million were attributable to smoking.

Global impact of TB

TB occurs in every part of the world. In 2020, the largest number of new TB cases occurred in the WHO South-East Asian Region, with 43% of new cases, followed by the WHO African Region, with 25% of new cases and the WHO Western Pacific with 18%.

In 2020, 86% of new TB cases occurred in the 30 high TB burden countries. Eight countries accounted for two thirds of the new TB cases: India, China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh and South Africa.

Symptoms and diagnosis

Common symptoms of active lung TB are cough with sputum and blood at times, chest pains, weakness, weight loss, fever and night sweats. WHO recommends the use of rapid molecular diagnostic tests as the initial diagnostic test in all persons with signs and symptoms of TB as they have high diagnostic accuracy and will lead to major improvements in the early detection of TB and drug-resistant TB. Rapid tests recommended by WHO are the Xpert MTB/RIF Ultra and Truenat assays.

Diagnosing multidrug-resistant and other resistant forms of TB (see Multidrug-resistant TB section below) as well as HIV-associated TB can be complex and expensive.

Tuberculosis is particularly difficult to diagnose in children.

Treatment

TB is a treatable and curable disease. Active, drug-susceptible TB disease is treated with a standard 6-month course of 4 antimicrobial drugs that are provided with information and support to the patient by a health worker or trained volunteer. Without such support, treatment adherence is more difficult.

Since 2000, an estimated 66 million lives were saved through TB diagnosis and treatment. (credits: WHO)

Check out this episode!

[vicky8588]

Tuberculosis Testing Market Size Share and Industry Outlook to 2028

Market Overview

The "Global Tuberculosis Testing Market" is expected to grow at a high CAGR of 5.2% during the forecasting period (2021-2028).

Tuberculosis (TB) is a communicable disease that is a major cause of ill health, one of the top 10 causes of death worldwide, and the leading cause of death from a single infectious agent. It is caused by the bacillus Mycobacterium tuberculosis, which is spread when sick people with TB expel bacteria into the air, for example, by coughing. It typically affects the lungs (pulmonary TB) but can also affect other sites. About a quarter of the world’s population is infected with M. tuberculosis and thus at risk of developing TB disease. Tuberculosis testing can be defined as the most commonly used diagnostic tool for tuberculosis. With a timely diagnosis and treatment with first-line antibiotics for 6 months, most people who develop TB can be cured, and onward transmission of infection curtailed. The number of TB cases occurring each year can also be driven down by reducing the prevalence of health-related risk factors for TB providing preventive treatment to people.

Download free sample: https://www.datamintelligence.com/download-sample/tuberculosis-testing-market

Market Dynamics

The market is driven by the increasing number of coronavirus cases, increasing the number of tuberculosis patients.  According to the World Health Organization (WHO), in 2017, an estimated 4.4 million people fell ill with TB, and an estimated 638,000 died because of the disease, which is more than half of global TB deaths. Factors propelling the market's growth include the increasing burden of tuberculosis and multidrug-resistant tuberculosis, increasing R&D investments, intensive product pipelines, and increasing government initiatives in the emerging markets. The landscape of TB diagnostics has changed dramatically during the past ten years. Moreover, in response to the WHO Global TB program, it has implemented a systematic and dynamic process used to evaluate technologies and develop policies, which has enhanced the market's growth.

The prevalence rate of tuberculosis is also increasing every year, along with the number of government awareness programs that influence people to opt for diagnostic tests (like radiographic tests), which are expected to drive the market during the forecast period. The market is also expected to witness growth as there is an opportunity for players in the market to accelerate their pipeline diagnostic products' market approval by spurring the fundamental research in TB. Additionally, technological developments in genomics and proteomics can be leveraged by diagnostic providers to hasten product development in TB diagnostics.

The increasing screening rate in the high burden regions, affordability of diagnostics, advanced methodologies, faster clinical decisions, and reduction in mortality rate are the focal areas of development. Improved preventive and curative diagnosis rates are the results of these initiatives. This has led to a subsequent upsurge in demand for diagnostic tests and the TB diagnostics market.

Furthermore, the government and independent healthcare organizations have undertaken initiatives to control this infectious disease's proliferation. Creating awareness about the importance of diagnosis is vital in increasing the screening and diagnosis rates, further helping the TB diagnostics market flourish. This factor is driving the growth of the market in the forecast period. For instance, the Revised National Tuberculosis Control Program (RNTCP) in India focuses on performing TB screening and providing greater access to treatment through free diagnosis & treatment programs. Besides, private-public partnerships under this program are boosting the diagnosis rate.

Population above the age of 60 is the target population for the TB diagnostics market as this demographic is susceptible to infectious diseases. The growing geriatric population base, as a result, is driving the growth of the market.

However, drug resistance in tuberculosis is one of the primary concerns for healthcare professionals as improper treatment due to wrong drug regimens and incorrect dosage forms lead to drug resistance in TB patients undergoing treatment, restraining the market's growth.

Segment Analysis

– By Test Type

·       Nuсlеіс Асіd Теѕtіng*

·       Cytokine Detection Assay

·       Detection of Latent Infection

·       Сulturе Ваѕеd Теѕtѕ

·       Drug Ѕuѕсерtіbіlіtу Теѕtіng

·       Others

– By End-User

·       Hospital laboratories*

·       Research laboratories

·       Clinics laboratories

·       Diagnostic center

Geographical Presentation

The global tuberculosis testing market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, Asia-Pacific dominated the global tuberculosis testing market and is expected to grow at the highest CAGR during the forecast period. The growth of the market in the region is attributed to tuberculosis's high burden and the rapid proliferation of this disease. The increasing prevalence of TB in Japan helps in the TB diagnostics market's growth. The high prevalence of TB creates an urgent demand for effective and quick diagnosis of the disease. Besides, in countries such as India, according to the recent budget announcement, the Government of India aims to eliminate tuberculosis by 2025, which is expected to act as one of the major factors for the growth of the Asia-Pacific market forecast period.

Infectious and Endemic Disease Control in China, RNTCP in India, and the National TB program in Afghanistan are the few programs planned by local healthcare agencies to contain the incidence and ensure equitable access to diagnosis. As per the WHO, countries such as India, China, Afghanistan, and Indonesia are priority regions for controlling this communicable disease.

The Middle East and Africa region are expected to have the third-largest share due to the relatively faster pace because of the increasing instances of tuberculosis. The increasing government focuses on establishing regulations to approve tuberculosis tests and growing focus on awareness programs by the tuberculosis diagnosis testing kits manufacturing companies. North America, powered by the U.S., is one of the major markets for the global tuberculosis testing market.

In October 2018, BD, a leading global medical technology company, announced the BD MAX™ MDR-TB panel availability in Europe. BD launched the first automated liquid culture system, the BD BACTEC™ MGIT™ system, for comprehensive drug susceptibility and resistance testing.

Competitive Analysis

The global tuberculosis testing market is highly competitive, with the presence of several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition. Thermo Fisher Scientific, Inc., Hologic Corporation, Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, bioMerieux SA, Sanofi, Cepheid, Hain Lifescience GmbH, are the leading market players with significant market share. The major players are using product development, novel product launches, market expansion, and product diversification strategies for holding their position in the market.

The companies are entering into collaborations, mergers, strategic partnerships, and acquisitions to expand their presence and meet the rising demand for the Treatment of COVID-19 across the globe.

For instance, in July 2016, bioMérieux launched a novel CE-marked database and reagents kit VITEK MS to identify TB. This new product launch is anticipated to help the company increase its market share.

In September 2017, Thermo Fisher Scientific, Inc. acquired Alfa Aesar for USD 400 million. Alfa Aesar is involved in providing laboratory and research chemicals ranging from catalysts, reagents, analytical, and labeling products. Their combined strength in laboratory chemical development and production is expected to support their growth in this sector.

View Full Report: https://www.datamintelligence.com/research-report/tuberculosis-testing-market

Enquiry Before Buying: https://www.datamintelligence.com/enquiry/tuberculosis-testing-market

About Us

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.

 For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: info@datamintelligence.com

Tel: +1 877 441 4866

Website: www.datamintelligence.com